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Correspondence 
Portacaval Shunt in Three Children with Alpha-I-Antitrypsin Deficiency 
and Cirrhosis: 9 to 121/3 Years Later 
To the Editor: 
Re,garding the elegant discussion ofliver transplan-
tation recently published by Maddrey and Van Thiel 
(1), we would like to comment on patients with alpha-
1-antitrypsin deficiency and liver disease whom we saw 
before the extensive use of liver transplantation. 
Evidence was published five years ago showing that 
end-to-side portacaval shunt in these patients may 
have favorably influenced the course of liver disease 
caUSled by alpha-I-antitrypsin deficiency (2). The op-
erations, on two girls and one boy, were performed on 
June 15, 1976; March 7, 1978 and November 1, 1979, 
when the children were 4%, 61h and 1% yr old, re-
spectively. At the time, the option of liver transplan-
tation was neither satisfactory nor widely available. 
All three children had had neonatal hepatitis and a 
history of bleeding esophageal varices, ascites or both. 
Phenotypes were PiZZ (Pi = protease inhibitor). Liver 
function was abnormal but not gravely perturbed 
(Table 1). 
The low serum alpha-I-antitrypsin levels were not 
appreciably different before and long after the porta-
cav~ll shunts (Table 1). All three children had normal 
physical growth, and Patients 1 and 3 remain osten-
sibly healthy. Patient 2 was frequently ill, with a record 
of&equent school absenteeism. Diuretics were required 
intermittently for control of her ascites. Her liver func-
tion test results were abnormal at the time of porta-
caval shunt. Her test results worsened immediately 
afterward (2) but then became stable for more than 9V2 
yr (Table 1). In October 1987, she developed acute liver 
decompensation and on November 3,1987, underwent 
succ:essful orthotopic liver transplantation at the Uni-
versity of California at Los Angeles. It was previously 
reported (2) that the serum ammonia rose after por-
tacaval shunt in all three patients and that the ami-
notransferase and alkaline phosphatase levels fell. The 
san:le pattern has persisted (Table 1) in Patients 1 and 
3, lneither of whom has practiced any dietary re-
striction. 
All three patients had macronodular cirrhosis at the 
time of portacaval shunt, with biopsy findings typical 
oftlhe liver disease associated with alpha-I-antitrypsin 
defi!ciency (2). The sample obtained from the excised 
liver in Patient 2 after 9'12 yr and the repeat biopsy 
sample in Patient 3 after 8% yr were fixed in buffered 
formalin. Patient 1 refused biopsy. Paraffin sections 
were prepared and stained with a variety of reagents, 
including periodic acid-Schiff stain, after the sec-
tions were treated with diastase. A peroxidase-
antiperoxidase technique with specific antibody (Oak-
opatts) was used to identify alpha-I-antitrypsin. A 
standard morphometrical method revealed 10,000 he-
patocytes in each liver sample (3). The proportion of 
hepatocytes with alpha-I-antitrypsin granules in the 
cytoplasm was recorded. 
Both livers remained cirrhotic, and the cytoplasm of 
some of the hepatocytes contained granules of alpha-
I-antitrypsin. Most of the granules were small and the 
number per cell varied greatly; they were more com-
mon at the periphery of the pseudolobules. When com-
pared with the liver biopsy specimens obtained at the 
time of portacaval shunting, the severity of the cirrho-
sis appeared unaltered, but in Patient 2 severe intra-
hepatic cholestasis that had not been present before 
was found. In Patients 2 and 3 the hepatocytes were 
approximately 20% smaller than when the portacaval 
shunt was performed. The percentage of hepatocytes 
containing alpha-1-antitrypsin also was lower. In Pa-
tient 2, it was 19.3% (compared with 38.2% in the pre-
shunt biopsy specimen and OUKR~ in a biopsy sample 
taken 9 mo later). In Patient 3, the percentage was 
19.05% (compared with 44.5% in the preshunt biopsy 
specimen, 48.2% 7 mo after portacaval shunting, 38.7lk 
at 13 mo and 20.4% at 2 yr, 11 mol (2). 
Portal diversion has been shown during the last 15 
yr to palliate three congenital errors of metabolism: 
glycogen storage disease (3), familial hypercholester-
olemia (4) and alpha-1-antitrypsin deficiency (2,5). Be-
cause each of these errors can be corrected far more 
effectively by liver transplantation (6-8), portacaval 
shunts for metabolic purposes in these diseases have 
been almost completely and appropriately abandoned. 
The presence of a shunt introduces a technical risk 
factor at the time of transplantation. However, there 
may be occasional patients such as ours with alpha-1-
antitrypsin deficiency, reasonable liver function and 
serious complications of portal hypertension, who sub-
mit to lifesaving portal diversion procedures when a 
liver cannot be found at the appropriate time. In our 
patients the process ofliver injury thought to be caused 
by the intracellular accumulation of irritating alpha-
I-antitrypsin particles that cannot be excreted at a nor-
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TABLE 1. Chemistries before end-to-side portacaval shunt and 80/3 to 12 yr later 
Normal Patient 1 Patient 2 Patient 3 
Age (yr) at testing 40/3 163/. S'Iz IS· 11/.2 93/. 
Serum bilirubin (ILmoIIL) <20 26 17 31 40 <20 25 
Serum limmonia (ILmollLl <40 59 116 29-S3 95 <40 75 
Serum AST (lUlL) <50 150 32 200 101 200 102 
Serum ALT (lU ILl <50 260 51 300 61 150 52 
Alkaline phosphatase (IU ILl <200 1,800 595 1,000 117 550 351 
Prothrombin time (sec) 11-11.5 12 12.8 13 15 11.5 12 
Serum alpha-l-antitryspin >2.0 0.3 0.5 0.16 <0.20 0.30 0.22 
(gmIL) 
Serum protein (gm/Ll >65 63 56 52 52 60 55 
Serum albumin (gm/L) >30 33 35 35 28 30 28 
'"These tests were in early October 1987, 1 mo before liver transplantation on November 3, 1987. Liver function deteriorated rapidly 
during thE. next few weeks, necessitating transplantation. 
the portacaval shunt selectively damaged the rough 
endoplasmic reticulum where the synthetic processes 
of the liver are concentrated without a commensurate 
reduction in excretory function of the hepatocytes. The 
result would be a more favorable relation between de-
position of the alpha globulin and its elimination from 
the hepatocytes. The histopathological findings in the 
livers of Patients 1 and 3 were consistent with this 
hypothesis in that the reduction in the size of the he-
patocytes and in the percentage of hepatocytes con-
taining alpha-I-antitrypsin granules noted in the ear-
lier biopsies (2) has been maintained. 
trophil elastase. A favorable effect on lung disease is 
expected from liver transplantation, although with a 
maximal follow-up of only 13 yr (16), it is too soon to 
be sure that this will be achieved_ 
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